In the midst of ongoing conflicts, U.S. President Donald Trump has once again shifted focus to tariffs. This time, he has issued an order imposing tariffs of up to 100% on foreign-branded pharmaceuticals. This significant policy change will directly impact pharmaceutical companies that manufacture drugs outside the United States. Trump has made it clear that these companies will not only need to reduce their prices but also shift their production to within the U.S.
According to the new regulations, companies that partially relocate their production to the U.S. will be subject to a 20% tax. In contrast, those that fail to comply will face a 100% tariff. Trump asserts that this decision will not only lower drug prices but also create job opportunities in the domestic manufacturing sector. Additionally, he has made significant changes to the regulations governing the production of metals such as steel, aluminum, and copper, reducing tariffs on several items and altering tax collection methods. The Trump administration has maintained a 50% tariff on imports of steel, aluminum, and copper under Section 232 of the Trade Act of 1974, while some metals now face a 25% tariff. ये खबर आप गज़ब वायरल में पढ़ रहे हैं। Furthermore, products containing less than 15% metal content are completely exempt from taxes. However, the method of tax collection has been slightly modified; the tariff will now be applied to the price paid by American consumers for the imported goods, rather than just the metal content.
To understand the rationale behind Trump's 100% tariffs, it's essential to look back a year when he imposed hefty taxes globally under the International Emergency Economic Powers Act (IEEPA) during a 'Liberation Day' initiative. This move sparked outrage in several countries and led to legal challenges. In February of this year, the U.S. Supreme Court deemed those previous taxes illegal, resulting in the Trump administration needing to refund $166 billion to those who had been taxed. To recover from this substantial loss and assert his position, Trump has introduced these new regulations.
As clarified in the announcement, the exemption for generic drugs will significantly benefit India. Indian companies dominate the global market for generic medications. Therefore, in the short term, the exemption will provide a safety net and facilitate the export of low-cost drugs, which are crucial to India's pharmaceutical trade with the U.S. A senior White House official informed a news agency that while generic drugs, which constitute a large portion of Indian pharma exports, are exempt from tariffs, the Commerce Department will evaluate the re-shoring status of these drugs and reassess tariffs accordingly.
